. Author manuscript; available in PMC: 2020 Mar 29.

Published in final edited form as: Gynecol Oncol. 2019 Dec 13;156(2):423–429. doi: 10.1016/j.ygyno.2019.12.003

Table 4.

Associations of each prognostic factors including EZH2 expression in primary tumor tissue with PFS.

Characteristic	Hazard ratio	95% CI	P-value^a
Age: high(>median) vs low(≤median)	2.422	0.789 to 8.942	0.1283
bmi: high(>median) vs low(≤median)	0.788	0.254 to 2.374	0.6683
EZH2 mRNA: high(>median) vs low(≤median)	0.59	0.178 to 1.769	0.3611
EZH2 protein (WB): negative vs positive	0.307	0.047 to 1.143	0.117
Stage: I/II vs III/IV	0.968	0.321 to 3.008	0.9534
Tumor grade: 1/2 vs 3	0.674	0.206 to3.005	0.5458
Tumor penetration: inner half vs outer half/serosa	0.752	0.242 to 2.263	0.6066
Cytology: negative vs positive/suspicious	1.153	0.297 to 7.562	0.8556
Nodal status: negative vs positive	0.664	0.201 to 2.538	0.5118
Vascular invasion: absent vs present	0.4	0.129 to 1.207	0.089

Score test from univariate Cox PH model except p-values for EZH2 expressions resulting from Monte-Carlo permutation-based log-rank tests.